Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers World Congress 2018

Jan Lötvall's Biography

Jan Lötvall, Professor and Chairman of Krefting Research Centre, University of Gothenburg; Chief Scientific Officer, Codiak Biosciences; Founding President of ISEV

Professor Jan Lötvall is a Swedish clinical allergist and scientist working on translational research primarily in the field of asthma. He is the director of the Krefting Research Centre at the University of Gothenburg. Prof. Lötvall led the research that discovered RNA in exosomes, showing a new communication route between cells by the transfer of RNA via exosomes. Prof. Lötvall started studying medicine at the Karolinska Institutet in Stockholm in 1981, but moved to Gothenburg in 1985 and graduated from the Medical School of the University of Gothenburg in 1987. He became interested in asthma research in the mid-1980s. After having studied for 2.5 years as a visiting fellow at the National Heart and Lung Institute, London, Prof. Lötvall defended his thesis in February 1991. He has done clinical training in both pharmacology and allergology, and became a specialist in each of these in 1997 and 1999 respectively. He became associate professor (docent) at the University of Gothenburg in 1993 and full professor of clinical allergology in 2002.

Professor Lötvall is Chief Scientific Officer at Codiak Biosciences, as well as the Founding President of ISEV.

Jan Lötvall Image

Subgroups of Extracellular Vesicles from Tumor Tissues for Biomarker Discovery and Liquid Biopsy Development in Malignant Disease

Wednesday, 28 March 2018 at 09:45

Add to Calendar ▼

Extracellular vesicles (EVs) have the capacity to shuttle both proteins, lipids and nucleotides such as RNA between cells, leading to an array of functional changes in a recipient cell. Importantly, the EV secretome changes significantly in disease, especially in cancer. We have recently developed a process to isolate EVs specifically from tumor tissues, and have utilized this technology to identify an array of biomarker candidates in malignant melanoma, breast cancer and colon cancer. Specifically, the technique identifies EV surface molecules from tumor tissue EVs, which are not present on plasma EVs from healthy individuals. Using this information, we have been able to develop assays to specifically identify cancer-EVs in the circulation in cancer patients compared to healthy individuals. This presentation will discuss EV diversity, and will give several examples of circulating cancer EV biomarkers that can function as liquid biopsies in cancer subgroup identification, cancer monitoring and putatively cancer screening.

Add to Calendar ▼2018-03-28 00:00:002018-03-29 00:00:00Europe/LondonCirculating Biomarkers World Congress 2018Circulating Biomarkers World Congress 2018 in Boston, USABoston,